Tagrisso shows survival benefit in NSCLC Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Tagrisso osimertinib met the primary endpoint of significantly improving progression-free survival (PFS) vs. platinum-based doublet chemotherapy in the confirmatory Phase III AURA3 study. The trial is evaluating Tagrisso as a second-line treatment for EGFR T790M mutation-positive, locally advanced or metastatic non-small cell lung cancer.

Tagrisso has accelerated approval from FDA and conditional approval from the European Commission in the indication. ...